Perkins Capital Management Inc. Purchases 335,429 Shares of Biodesix, Inc. (NASDAQ:BDSX)

Perkins Capital Management Inc. increased its holdings in shares of Biodesix, Inc. (NASDAQ:BDSX - Free Report) by 46.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,060,211 shares of the company's stock after acquiring an additional 335,429 shares during the period. Biodesix comprises approximately 1.4% of Perkins Capital Management Inc.'s holdings, making the stock its 23rd largest holding. Perkins Capital Management Inc. owned approximately 0.73% of Biodesix worth $1,622,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BDSX. Wilmington Savings Fund Society FSB acquired a new position in Biodesix in the third quarter worth $10,849,000. Geode Capital Management LLC raised its holdings in shares of Biodesix by 50.7% in the third quarter. Geode Capital Management LLC now owns 804,576 shares of the company's stock valued at $1,433,000 after buying an additional 270,724 shares during the last quarter. Stephens Inc. AR acquired a new position in Biodesix during the 4th quarter worth about $303,000. HighTower Advisors LLC grew its holdings in Biodesix by 17.1% during the 4th quarter. HighTower Advisors LLC now owns 153,934 shares of the company's stock worth $236,000 after acquiring an additional 22,500 shares during the last quarter. Finally, Landscape Capital Management L.L.C. acquired a new stake in Biodesix in the 3rd quarter valued at about $262,000. 20.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, William Blair reiterated an "outperform" rating on shares of Biodesix in a research report on Tuesday, March 4th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Biodesix presently has a consensus rating of "Buy" and a consensus target price of $2.95.

Biodesix Trading Down 6.0 %

BDSX stock traded down $0.04 during midday trading on Friday, reaching $0.67. The stock had a trading volume of 157,705 shares, compared to its average volume of 292,441. The firm has a market cap of $97.81 million, a price-to-earnings ratio of -1.72 and a beta of 1.10. Biodesix, Inc. has a twelve month low of $0.64 and a twelve month high of $2.04. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30. The business has a fifty day simple moving average of $0.89 and a two-hundred day simple moving average of $1.29.

Biodesix (NASDAQ:BDSX - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01. Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. The company had revenue of $20.43 million during the quarter, compared to analysts' expectations of $19.92 million. As a group, research analysts expect that Biodesix, Inc. will post -0.35 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Scott Hutton sold 83,660 shares of the firm's stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total value of $76,967.20. Following the transaction, the chief executive officer now directly owns 701,947 shares in the company, valued at $645,791.24. This trade represents a 10.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders sold 128,702 shares of company stock valued at $118,406. Company insiders own 69.20% of the company's stock.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.